Evidence map›Paper›PMID 37758302›Full record

ArticleBioconjugate chemistry2023

Self-Adjuvanting TLR7/8 Agonist and Fentanyl Hapten Co-Conjugate Achieves Enhanced Protection against Fentanyl Challenge.

Noah Powers, Casey Massena, Bethany Crouse, Mira Smith, Linda Hicks, Jay T Evans, Shannon Miller, Marco Pravetoni, David Burkhart

Open access · hybridAbstract read
In one paragraph

Article in Bioconjugate chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. A novel cationic liposome-formulated toll like receptor (TLR) 7/8 agonist enhances the efficacy of a vaccine against fentanyl toxicity.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Noah PowersCenter for Translational Medicine, Department of Biomedical and Pharmaceutical Sciences, University of Montana, 32 Campus Drive, Skaggs Building, Missoula, Montana 59801, United States.ORCID 0009-0007-6422-0220
Casey MassenaCenter for Translational Medicine, Department of Biomedical and Pharmaceutical Sciences, University of Montana, 32 Campus Drive, Skaggs Building, Missoula, Montana 59801, United States.
Bethany CrouseDepartment of Pharmacology, University of Minnesota, Minneapolis, Minnesota 55455, United States.ORCID 0000-0002-1984-2465
Mira SmithCenter for Translational Medicine, Department of Biomedical and Pharmaceutical Sciences, University of Montana, 32 Campus Drive, Skaggs Building, Missoula, Montana 59801, United States.
Linda HicksCenter for Translational Medicine, Department of Biomedical and Pharmaceutical Sciences, University of Montana, 32 Campus Drive, Skaggs Building, Missoula, Montana 59801, United States.
Jay T EvansCenter for Translational Medicine, Department of Biomedical and Pharmaceutical Sciences, University of Montana, 32 Campus Drive, Skaggs Building, Missoula, Montana 59801, United States.
Shannon MillerCenter for Translational Medicine, Department of Biomedical and Pharmaceutical Sciences, University of Montana, 32 Campus Drive, Skaggs Building, Missoula, Montana 59801, United States.
Marco PravetoniDepartment of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington 98195, United States.
David BurkhartCenter for Translational Medicine, Department of Biomedical and Pharmaceutical Sciences, University of Montana, 32 Campus Drive, Skaggs Building, Missoula, Montana 59801, United States.
University of Montana · USUniversity of Minnesota · USUniversity of Washington · US

Funding

Vaccines for fentanyl and its derivatives: A strategy to reduce illicit use and overdoseUH3DA048386 · NIDA · UNIVERSITY OF WASHINGTON · PI PRAVETONI, MARCO · 2022 to 2024
$11.0M
Fusion: Vaccine conjugate technology to advance vaccine safety and efficacyR01AI137146 · NIAID · UNIVERSITY OF MONTANA · PI RYTER, KENDAL · 2018 to 2022
$3.3M
Vaccines for fentanyl and its derivatives: A strategy to reduce illicit use and overdoseUG3DA048386 · NIDA · UNIVERSITY OF MINNESOTA · PI PRAVETONI, MARCO · 2019 to 2020
$3.3M
Identifying mechanisms and biomarkers predictive of individual variability in efficacy of vaccines against opioid use disorderF31DA054760 · NIDA · UNIVERSITY OF MINNESOTA · PI CROUSE, BETHANY K · 2021 to 2021
$27k
NIAID NIH HHS 75N93020C00039NIAID NIH HHS R01 AI137146NIDA NIH HHS F31 DA054760NIDA NIH HHS UG3 DA048386NIDA NIH HHS UH3 DA048386
6 · The paper itself

Abstract

Currently approved pharmacotherapies for opioid use disorders (OUDs) and overdose reversal agents are insufficient to slow the spread of OUDs due to the proliferation of fentanyl. This is evident in the 31% rise in drug overdose deaths from 2019 to 2022, with rates increasing from 21.6 to 28.3 overdoses per 100,000 deaths. Vaccines are a potential alternative or adjunct therapy for the treatment of several substance use disorders (nicotine, cocaine) but have shown limited clinical success due to suboptimal antibody titers. In this study, we demonstrate that coconjugation of a Toll-like receptor 7/8 (TLR7/8) agonist (UM-3006) alongside a fentanyl-based hapten (F

Indexed as

Opioid-Related DisordersVaccinesAdjuvants, ImmunologicAnalgesics, OpioidAnimalsAntigensFentanylHaptensMiceToll-Like Receptor 7Adjuvants, ImmunologicAnalgesics, OpioidAntigensFentanylHaptensToll-Like Receptor 7Vaccines

Identifiers

PMID37758302
PMCPMC10587865
OpenAlexW4387079244

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.